Literature DB >> 1867181

Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL).

G Banfi1, T Bertani, V Boeri, T Faraggiana, G Mazzucco, G Monga, G Sacchi.   

Abstract

The frequency of renal vascular lesions (RVL) and their relevance in the progression of renal damage were evaluated by the Pathology Group of the "Gruppo Italiano per lo Studio della Nefrite Lupica" (GISNEL). Of 285 patients with lupus nephritis collected from 20 nephrology centers in Italy and classified according to World Health Organization (WHO) criteria, 79 cases (27.7%) with RVL were identified and classified as follows: (1) lupus vasculopathy (n = 27); (2) hemolytic-uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP) malignant hypertension-like lesions (n = 24); (3) vasculitis (n = 8); (4) arterio-arteriosclerosis (n = 20). At the time of renal biopsy, patients with RVL had mean serum creatinine levels significantly higher than patients without RVL (201.8 +/- 195.9 mumol/L [2.2 +/- 2.2 mg/dL] v 108.1 +/- 108.0 mumol/L [1.2 +/- 1.2 mg/dL]; P less than 0.01). Hypertension was more frequent in patients with RVL than in those without (68.4% v 30.5%; P less than 0.01). The probability of kidney survival assessed according to the Kaplan-Meier method at 5 and 10 years was, respectively, 74.3% +/- 5.9% and 58.0% +/- 8.9% in patients with RVL, compared with 89.6% +/- 2.7% and 85.9% +/- 3.7% in patients without RVL. However, the two groups did not differ significantly as regards overall survival, the probability of survival at 5 and 10 years being 86.5% +/- 4.5% and 78.8% +/- 6.6% in patients with RVL and 92.2% +/- 2.2% and 83.3% +/- 4.4% in patients without RVL.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1867181     DOI: 10.1016/s0272-6386(12)80885-7

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  32 in total

1.  Soluble VEGF receptor 1 promotes endothelial injury in children and adolescents with lupus nephritis.

Authors:  Monika Edelbauer; Sudhir Kshirsagar; Magdalena Riedl; Heiko Billing; Burkhard Tönshoff; Dieter Haffner; Jörg Dötsch; Gottfried Wechselberger; Lutz T Weber; Elisabeth Steichen-Gersdorf
Journal:  Pediatr Nephrol       Date:  2011-12-07       Impact factor: 3.714

2.  Rapidly progressive lupus nephritis and concomitant thrombotic microangiopathy.

Authors:  Chems Gharbi; Edward Bourry; Philippe Rouvier; Sabria Hacini; Ahmed Letaief; Alain Baumelou; Hassane Izzedine
Journal:  Clin Exp Nephrol       Date:  2010-06-11       Impact factor: 2.801

Review 3.  Renal involvement in antiphospholipid syndrome.

Authors:  Francisco Vileimar Andrade de Azevedo; Diego Germano Maia; Jozelio Freire de Carvalho; Carlos Ewerton Maia Rodrigues
Journal:  Rheumatol Int       Date:  2018-05-05       Impact factor: 2.631

Review 4.  The Revisited Classification of GN in SLE at 10 Years: Time to Re-Evaluate Histopathologic Lesions.

Authors:  Suzanne Wilhelmus; Charles E Alpers; H Terence Cook; Franco Ferrario; Agnes B Fogo; Mark Haas; Kensuke Joh; Laure-Hélène Noël; Surya V Seshan; Jan A Bruijn; Ingeborg M Bajema
Journal:  J Am Soc Nephrol       Date:  2015-07-07       Impact factor: 10.121

5.  Renal thrombotic microangiopathy associated to worse renal prognosis in Lupus Nephritis.

Authors:  Fernando Louzada Strufaldi; Precil Diego Miranda de Menezes Menezes Neves; Cristiane Bitencourt Dias; Luis Yu; Viktoria Woronik; Livia Barreira Cavalcante; Denise Maria Avancini Costa Malheiros; Lectícia Barbosa Jorge
Journal:  J Nephrol       Date:  2021-02-11       Impact factor: 3.902

6.  Evaluation of clinical outcomes and renal vascular pathology among patients with lupus.

Authors:  Claire Barber; Andrew Herzenberg; Ellie Aghdassi; Jiandong Su; Wendy Lou; Gan Qian; Jonathan Yip; Samih H Nasr; David Thomas; James W Scholey; Joan Wither; Murray Urowitz; Dafna Gladman; Heather Reich; Paul R Fortin
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-22       Impact factor: 8.237

Review 7.  Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.

Authors:  Maria Izabel de Holanda; Luis Cristóvão Pôrto; Teresa Wagner; Luis Fernando Christiani; Lilian M P Palma
Journal:  Clin Rheumatol       Date:  2017-09-13       Impact factor: 2.980

Review 8.  Renal involvement in primary antiphospholipid syndrome.

Authors:  Carmelita Marcantoni; Carmela Emmanuele; Francesco Scolari
Journal:  J Nephrol       Date:  2016-05-19       Impact factor: 3.902

Review 9.  Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy.

Authors:  Maria G Tektonidou
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

10.  Lupus vasculopathy combined with acute renal failure in lupus nephritis.

Authors:  Chien-Te Wu; Lin-Shien Fu; Mei-Chin Wen; Shein-Chung Hung; Ching-Shiang Chi
Journal:  Pediatr Nephrol       Date:  2003-10-24       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.